Objective. To examine the relationship between MRI structural damage and repair and plasma inflammatory cytokines in patients with RA.
Introduction
Preventing structural damage is one of the most significant goals in the treatment of RA. Many studies have researched predictive factors for radiographic progression, such as bone erosion on X-ray at an early stage, positive RF or anti-CCP antibodies, and high levels of serum inflammatory markers, including CRP and ESR, as signs of poor outcome [1, 2] . MRI in RA is an imaging modality that has recently been shown to improve discriminative sensitivity over that of traditional X-ray regarding structural damage and repair [35] . The usefulness of MRI is well validated, and it is promising to be valuable in many clinical studies because in early RA erosion progression by MRI score (RAMRIS) correlates with futuristic radiographic progression; thus the sample size and observation period can be decreased [6, 7] . With respect to MRI erosion progression, some studies reported that it associated with synovial thickness and bone oedema score on MRI [8] .
Plasma cytokines, including TNF-a, IL-1 and IL-6, play an important role in the pathogenesis of RA, precipitating the inflammation of joint tissues and leading to bone resorption via osteoclast differentiation [9] . However, the relationship between structural damage progression and repair on X-ray and MRI to RA, and the relevance of plasma cytokines, is still unclear. We previously reported that IL-6 levels after treatment were associated with radiological progression of damage on X-ray, but those before treatment did not predict this progression [10] . Therefore, we assessed structural damage progression by the more sensitive MRI technique to determine its relationship with pre-treatment cytokines.
The aim of this study was to evaluate the effect of serum cytokines on structural changes detected by MRI in patients with RA.
Methods

Patients and data collection
We enrolled 88 newly diagnosed, untreated patients with RA who were diagnosed based on the 1987 ACR RA criteria or the 1994 Japanese College of Rheumatology early RA criteria.
Demographic and clinical characteristics were obtained from medical records. These included age, sex, arthritic symptom duration, tender joint count, swollen joint count, ESR, CRP, MMP-3, RF, anti-CCP antibody and mean DAS using ESR for 28 joints (DAS28).
All patients were scheduled to undergo 1.5 Tesla MRI (Singna, GE Medical Systems, Milwaukee, WI, USA) with contrast enhancement of the dominant hand periodically, and X-ray of both hands and feet. They also provided peripheral blood before and after starting treatment. This study was approved by the Ethics Committee of Keio University School of Medicine, and all patients provided written informed consent.
Cytokine concentrations
Plasma levels of 10 cytokines were measured by electrochemiluminescence assay using the Ultra-Sensitive Kit (Meso Scale Discovery, MD, USA): IL-6, VEGF, IL-1b, TNF-a, IL-8, GM-CSF, IFN-g, IL-2, IL-10 and IL-12p70. During measurement, immunoglobulin-inhibiting reagent (Bioreclamation, NY, USA) was added to prevent interference by heterophilic antibodies.
Evaluation of MRI and X-rays
MRIs of the dominant hand at baseline and at 1 year were assessed in accordance with the latest OMERACT RAMRIS. MRI sequences included imaging in two planes, with T1-weighted imaging before and after intravenous gadolinium contrast, and a T2-weighted fat-saturated sequence. Images were scored by two experienced radiologists (H.S. and S.M.) who were blind to the patients' clinical information [11] . The mean score of the two readers was used in the analysis. The baseline and 1-year X-rays of the hand corresponding to the MRI were scored using the modified total Sharp score (mTSS) by two rheumatologists (Y.K. and Y.K.) who were also blind to the patients' information, and the mean score was used [12] . Erosion progression was defined as changes in RAMRIS erosion score or mTSS erosion of > 0.5, and erosion repair was defined as erosion score changes of less than À0.5 [3, 12].
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics version 23.0 (IBM Corporation, NY, USA). Continuous data were presented as the mean with S.D., or the median with interquartile range. Univariate logistic analysis on MRI erosion progression was performed with all clinical parameters and MRI findings. Multivariate logistic regression analysis was conducted with variables whose univariate analysis resulted in a P < 0.05, including baseline DAS28, seropositivity for anti-CCP or RF, and CRP as independent variables, with a variance inflation factor of <5 for validation of multicollinearity in linear regression models [1] . The predictive accuracy of IL-6 association with MRI erosion progression was estimated by using receiver operating characteristic curve analysis with an area under the curve having 95% CIs. The KruskalWallis test was applied for analysis of variance and the JonckheereTerpstra test for trends in binomial proportions.
Results
Patient characteristics
Demographic characteristics, cytokine levels, RAMRIS score and mTSS at baseline and at 1 year for 88 patients are shown in supplementary Table S1, available at Rheumatology Online. Seventy-two (81%) patients were female, the mean age was 58 years and the mean symptom duration was 3.2 months. The mean DAS28 was 4.8. Sixty-two (70%) and 66 (74%) were positive for RF and anti-CCP, respectively. The DAS28 decreased from baseline to 2.6 at 1 year. Sixty-four percent were EULAR good responders. Treatments are summarized in supplementary Table S2 , available at Rheumatology Online.
Progression and repair in RAMRIS score and mTSS MRI synovitis and osteitis scores decreased during the first year, with a mean change of 3.9 and 1.5, respectively, while the mean MRI erosion score increased from 7.5 to 8.5. The changes in RAMRIS erosion scores were more dynamic than mTSS when assessing progression and repair of bone erosion, as shown in Fig. 1 (erosion progression, 52% vs 26%, P < 0.001; repair, 26% vs 15%, P = 0.003, respectively). If erosion progression for MRI was defined as >1.0 and >1.5, 41% and 40%, respectively, of these patients had erosion progression.
Because total erosion scores in RAMRIS and in mTSS differed, we calculated adjusted RAMRIS erosion and mTSS erosion by dividing the change (Á) in each erosion score by the respective total erosion score (MRI, 230; mTSS, 80) so as to make a numerical comparison. This also showed that MRI more sensitively captured changes in the bone erosion score than X-ray did (supplementary Fig. S1 , available at Rheumatology Online).
Factors associated with MRI erosion progression
Univariate logistic regression analysis revealed that MRI erosion progression was significantly associated with baseline RAMRIS osteitis (P = 0.012) and erosion scores (P = 0.011), baseline plasma IL-6 (P = 0.007), VEGF (P = 0.046) and CRP (P = 0.031), whereas no clinical parameters or cytokines were associated with mTSS erosion progression (data not shown). Multivariate logistic regression analysis using those significant variables and previously reported predictive values, including disease activity and seropositivity, as independent variables with consideration of multicollinearity revealed that the baseline IL-6 levels and seropositivity were independent predictive factors for MRI erosion progression during the first year, while VEGF and CRP were eliminated as predictive factors (supplementary Table S3 , available at Rheumatology Online).
The receiver operating characteristic curve found a baseline IL-6 level of 7.6 pg/ml discriminated MRI erosion progression during the first year from non-progression during the same time frame, with an area under the curve of 0.82, a sensitivity of 69% and a specificity of 95% ( Fig. 2A) . When we compared the proportion of erosion progression between four groups divided by the 7.6 pg/ml IL-6 level and seropositivity, the patients with IL-6 levels 57.6 pg/ml showed higher erosion progression rates regardless of their seropositivity status than those with IL-6 levels <7.6 pg/ml (Fig. 2B) . Next, we divided the patients into two groups based on an IL-6 level of 7.6 pg/ml (57.6 pg/ml and <7.6 pg/ml), and then divided each two group into a further two groups using the median IL-6 level of each group (13.5 pg/ml in the former group and 3.4 pg/ml in the latter group), creating four groups (high IL-6, moderatehigh IL-6, moderatelow IL-6 and low IL-6). The MRI erosion progression was significantly dependent on baseline IL-6 concentration ( Fig. 2C , P < 0.001). While erosions in MRI significantly increased in the high and the moderatehigh IL-6 groups (P < 0.05), the moderatelow and the low IL-6 group showed repair of MRI erosion, even though biologic agents were initiated more frequently in the high and moderatehigh IL-6 groups than in the moderatelow and low groups (35.3, 29.4, 18.5 and 15.3%, P = 0.032, respectively). No difference was found in DAS28-ESR at either baseline or 1 year between any of the four groups (supplementary Fig.  S2 , available at Rheumatology Online).
Prediction of MRI erosion repair
Although Fig. 2C shows that the changes in erosion score in patients with low baseline IL-6 levels were minus quantities, 23 of these patients had no erosion at baseline. Therefore, in order to focus on erosion repair, we extracted 71 patients who had had MRI erosion at baseline and divided them into three groups; the repair group (n = 23, defined as ÁRAMRIS less than À0.5), the non-change group (n = 11, defined as À0.5 4 ÁRAMRIS 4 0.5) and the progression group (n = 37, defined as ÁRAMRIS > 0.5). Whereas clinical parameters, including symptomatic duration and disease activities, were not statistically significantly different between the three groups (data not shown), baseline plasma IL-6 (P < 0.001) and VEGF (P = 0.017) were significantly lower in the repair and non-change group than in the progression group (supplementary Fig. S3 , available at Rheumatology Online). Multivariate logistic regression analysis (with factors including baseline IL-6, VEGF, baseline DAS28, symptomatic duration and the use of biologics) demonstrated that a low plasma IL-6 level was the only significant factor for MRI erosion repair (supplementary Table S4 , available at Rheumatology Online).
Discussion
This study demonstrated that MRI is more sensitive in terms of detecting erosion progression and repair than traditional X-ray, and pre-treatment plasma IL-6 levels were strongly associated with MRI erosion progression.
A previous study showed that MRI can detect bone erosions three times as sensitively as X-ray in early RA patients [13] . Moreover, MRI erosions could be detected ahead of X-ray erosions in the same patients [6, 14] . Our results demonstrating that progression in MRI erosion at 1 year was more acute than that revealed by X-ray are   FIG. 1 One year changes in erosion score of RA MRI score and modified total Sharp score Progression and repair in bone erosion were more frequently observed in MRI than in X-ray. ÁRAMRIS, 1-year changes in RA MRI scoring system; ÁmTSS, 1-year changes in modified total Sharp score.
www.rheumatology.oxfordjournals.org consistent with those studies. Progression in RAMRIS erosion score has been regarded as important, being widely used in clinical trials because it can demonstrate a difference in structural damage progression between groups with a smaller number of patients for shorter time periods than can X-ray [6, 7] .
Our study shows that plasma IL-6 before treatment is an independent and important relevant factor with respect to bone erosion, with subsequent erosive damage being sensitively detected by MRI. The relationship between IL-6 and joint destruction has been shown in several basic and clinical research studies. The IL-6 signalling pathway is not only important in synovial inflammation, but also in elevating RANK ligand (RANKL) expression, which induces osteoclastogenesis, directly leading to bone erosion [15] . Reduction in plasma IL-6, but not TNF-a, during MTX treatment was a strong indicator for radiographic progression [10] . Plasma IL-6 levels at the 1-year follow-up were associated with rapid joint destruction in X-rays of RA patients treated with a TNF inhibitor [16] . Suppressing IL-6 in RA has proven to be of great importance in preventing structural damage at the early stage in patients with high IL-6 levels. However, our study did not identify the biologic agents relevant to erosion progression or repair-this could be because of the small number of patients who had started biologic agents (only 16% used biologic agents for >6 months). Also, only four patients started tocilizumab, which hampered a further analysis regarding the impact of antiIL-6 treatment on erosion detected by MRI. We should examine this in future.
This is the first known study to show that the baseline plasma IL-6 level is also important for bone erosion repair. Knowledge about the pathophysiological and clinical backgrounds of bone erosion repair in RA, especially that sensitively detected by MRI, US or mCT, is limited [3, 17] . A previous study showing low bone formation in transgenic mice for IL-6 suggested that IL-6 acts on osteoblast lineage cells (blocking osteoblast function) as well as on osteoclasts (by facilitating RANKL) [18] . On the other hand, some studies have indicated an important role for the physiological concentration of IL-6 in recruiting and differentiating osteoblasts through insulin-like growth factor induction [19, 20] . Taken together, IL-6 should be stabilized at physiological levels to maintain a balance between osteoblasts and osteoclasts. From our results, we assume that low IL-6 levels at the time of RA diagnosis could be easily kept at optimum levels after joint inflammation suppression, resulting in osteoblast dominancy, leading to restoration of bone erosion.
Our study has some limitations. First, although we examined 10 cytokines that are well known to be critical in RA, cytokines involved in the pathogenesis of RA are abundant and we did not examine many of them, such as IL-17 or IL-33 [9] . Second, we examined plasma cytokine levels but not synovial production or expression. Third, we did not measure IL-6 levels at the 1-year mark. Therefore, the association between the decrease in IL-6 and erosion progression was unclear.
In conclusion, in newly diagnosed, untreated patients with RA, the plasma IL-6 level was a strong, independent   FIG. 2 The relationship of baseline IL-6 levels with MRI erosion progression (A) ROC curve showed an IL-6 level of 7.6 pg/ml could discriminate MRI erosion progression from non-progression. (B) MRI erosion progression rates were higher in the patients with IL-6 57.6 pg/ml than those without, regardless of their seropositivity status. (C) RAMRIS erosion scores significantly increased, dependent on baseline IL-6 concentration. AUC, area under the curve; ÁRAMRIS, 1-year changes in RA MRI scoring system. biomarker associated with subsequent erosive progression and restoration of bone. Such erosive progression and restoration was sensitively detected by MRI. Pharma Inc., Chugai Pharmaceutical Co., Ltd, Eizai Co., Ltd, Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co., Ltd and Wyeth. The sponsor of the study had no role in the study design, conduct of the study, data collection, data interpretation or preparation of the report. None of the authors has financial or personal relationships with people or organizations that could inappropriately influence or bias the content of this article. 
